Search Results
Jun 25, 2025, 09:13 ET Texas Women Songwriters Festival Announces First Wave of Headliners
Walker Foundation, Austin-Telco Federal Credit Union, Strait Music Company, YETI, Austin Chronicle, Lockhart Initiative for Tourism, KLKT Radio Lockhart, BMI, Howlin' Dog Music Group, Lucky Star Art Camp, You Rock Studio, and TeXchromosome. Sponsorships are still available—let your brand take the
More news about: Texas Women Songwriters Festival
Jun 25, 2025, 08:17 ET Annals of Family Medicine: Body Fat Percentage Beats BMI in Predicting 15-Year Mortality Risk Among U.S. Adults Ages 20 to 49
Medicine finds that body-fat percentage is a stronger predictor of 15-year mortality risk in U.S. adults than body mass index (BMI). Although BMI is widely used in clinics as the standard measure of body composition, it can potentially misclassify muscular individuals
More news about: Annals of Family Medicine
Jun 25, 2025, 07:03 ET Viking Therapeutics Announces Initiation of Phase 3 Obesity Clinical Program with GLP-1/GIP Agonist VK2735
injection once weekly for 78 weeks. The VANQUISH-1 study will target enrollment of approximately 4500 adults who are obese (BMI ≥30 kg/m2) or who are overweight (BMI ≥27 kg/m2) with at least one weight-related co-morbid condition. The VANQUISH-2 study will target enrollment of approximately
More news about: Viking Therapeutics, Inc.
Jun 24, 2025, 08:00 ET Rivus Pharmaceuticals Announces Positive Topline Results from Phase 2 M-ACCEL Trial of HU6 Showing Significant Reductions in Liver Fat in Patients with MASH
advanced liver fibrosis (consistent with stages F2 to F3 fibrosis), the risk of adverse liver outcomes increases dramatically. Increased body mass index (BMI) is one of the most important risk factors for developing MASH along with cardiovascular disease (CVD) and Type 2 diabetes. MASH is caused by an accumulation
More news about: Rivus Pharmaceuticals
Jun 23, 2025, 21:07 ET BrightGene presenteert positieve fase 2 gegevens voor de duale GLP-1R/GIPR agonist voor gewichtsbeheersing en type 2 diabetes, en preklinische gegevens voor een nieuw amylin-analoog tijdens de 85e wetenschappelijke sessies van de American Diabetes Association
Deelnemende proefpersonen waren volwassenen met een BMI ≥ 24 kg/m2 (gemiddelde BMI bij inclusie ≥ 27 kg/m2) met prediabetes en/of ten minste één comorbiditeit gerelateerd aan obesitas, of volwassenen met obesitas (BMI ≥ 28 kg/m2, gemiddelde BMI bij inclusie ≥ 30 kg/m2). De deelnemers werden
More news about: Bright Gene
Jun 23, 2025, 21:05 ET BrightGene präsentiert positive Phase-2-Daten für den Dual-GLP-1R/GIPR-Agonisten zur Gewichtsregulation und Behandlung von Typ-2-Diabetes sowie präklinische Daten für ein neues Amylin-Analogon bei den 85 Wissenschaftlichen Sitzungen der American Diabetes Association
Teilnehmer waren Erwachsene mit einem BMI ≥ 24 kg/m2 (durchschnittlicher BMI bei Aufnahme ≥ 27 kg/m2) mit Prädiabetes und/oder mindestens einer adipositasbezogenen Begleiterkrankung, oder Erwachsene mit Adipositas (BMI ≥ 28 kg/m², durchschnittlicher BMI bei Aufnahme ≥ 30 kg/m2). Die Teilnehmenden
More news about: Bright Gene
Jun 23, 2025, 21:03 ET BrightGene Presents Positive Phase 2 Data for Dual GLP-1R/GIPR Agonist for Weight Management and Type 2 Diabetes and Preclinical Data for Novel Amylin Analog at American Diabetes Association's 85th Scientific Sessions
(subcutaneous injection). Enrolled participants included adults with a BMI ≥ 24kg/m2 (mean BMI at enrollment ≥ 27kg/m2) with prediabetes and/or at least one obesity-related comorbidity, or adults with obesity (BMI≥ 28kg/m2, mean BMI at enrollment ≥ 30kg/m2). Participants were randomized into
More news about: Bright Gene
Jun 23, 2025, 20:54 ET BrightGene Menyajikan Data Fase 2 yang Positif untuk Agonis Ganda GLP-1R/GIPR untuk Pengelolaan Berat Badan dan Diabetes Tipe 2 serta Data Praklinis untuk Analog Amylin Baru di Sesi Ilmiah ke-85 Asosiasi Diabetes Amerika
yang direkrut adalah orang dewasa dengan BMI ≥ 24kg/m2 (rata-rata BMI saat pendaftaran ≥ 27kg/m2) dengan pradiabetes dan/atau setidaknya satu komorbiditas terkait obesitas, atau orang dewasa dengan obesitas (BMI ≥ 28kg/m², rata-rata BMI saat pendaftaran ≥ 30kg/m²). Peserta diacak
More news about: Bright Gene
Jun 23, 2025, 20:54 ET BrightGene Presents Positive Phase 2 Data for Dual GLP-1R/GIPR Agonist for Weight Management and Type 2 Diabetes and Preclinical Data for Novel Amylin Analog at American Diabetes Association's 85th Scientific Sessions
(subcutaneous injection). Enrolled participants included adults with a BMI ≥ 24kg/m2 (mean BMI at enrollment ≥ 27kg/m2) with prediabetes and/or at least one obesity-related comorbidity, or adults with obesity (BMI≥ 28kg/m2, mean BMI at enrollment ≥ 30kg/m2). Participants were randomized into
More news about: Bright Gene
Jun 23, 2025, 11:12 ET Cerapedics Announces FDA Approval of PearlMatrix™ P-15 Peptide Enhanced Bone Graft, The First and Only Proven Bone Growth Accelerator for Lumbar Fusion
and 293 patients, including approximately 60 percent of patients that were considered high risk for non-union (i.e., patients with Type 2 diabetes, BMI ≥ 30 and/or nicotine users). The study met the primary endpoint of 24-month Composite Clinical Success (CCS) and further demonstrated statistical superiority
More news about: Cerapedics Inc.
Jun 23, 2025, 11:00 ET Dialysis Equipment Market Size to Reach USD 19.14 Billion by 2031, Growing Cases of Chronic Kidney Diseases to Drive Market Growth | Business Market Insights
/PRNewswire/ -- According to a new comprehensive report from Business Market Insights, as per the latest market research by Business Market Insights (BMI), the research report "The Dialysis Equipment Market forecasts the market to expand from US$ 12.85 billion in 2024 to US$ 19.14 billion by 2031, registering
More news about: Business Market Insights
Jun 23, 2025, 10:45 ET Medical Endoscopes Market Size to Surpass USD US$ 22.46 Billion by 2031, exhibiting a CAGR of 6.5% | Business Market Insights
/PRNewswire/ -- According to a new comprehensive report from Business Market Insights, As per the latest market research by Business Market Insights (BMI), the research report "Medical Endoscopes Market Size and Forecast expand from US$ 14.49 Billion in 2024 to US$ 22.46 Billion by 2031, registering a
More news about: Business Market Insights
Jun 23, 2025, 10:30 ET Laparoscopic Devices Market Size to Hit US$ 26.61 billion by 2031, Growing Cases of Chronic Diseases to Drive Market: Report by Business Market Insights
As per the latest market research by Business Market Insights (BMI), the research report 'Laparoscopic Devices Market Size and Forecast (2021–2031)' forecasts how the market is set to surge 91% by 2031 as Growing Cases
More news about: Business Market Insights
Jun 22, 2025, 09:00 ET CagriSema 2.4 mg / 2.4 mg demonstrated 22.7% mean weight reduction in adults with overweight or obesity in REDEFINE 1, published in NEJM
showed that half (50.7%) of trial participants with obesity treated with CagriSema reached the threshold for non-obesity (BMI <30 kg/m2) at the end of treatment, from a mean BMI of 38 kg/m2 at the start of treatment. In the placebo group, 10.2% reached that threshold at 68 weeks.1
More news about: NOVO NORDISK INC.
Jun 21, 2025, 14:30 ET Semaglutide Increases Walking Capacity in Patients with Peripheral Artery Disease and Type 2 Diabetes
were observed independent of baseline levels of A1C, duration of diabetes, or intensity of diabetes. Furthermore, the benefits were seen across all BMI categories and regardless of the treatment with SGLT2 inhibitors. "These findings indicate that clinicians can now recognize semaglutide as a
More news about: American Diabetes Association
Jun 21, 2025, 09:01 ET Lilly's oral GLP-1, orforglipron, showed compelling efficacy and a safety profile consistent with injectable GLP-1 medicines, in complete Phase 3 results published in The New England Journal of Medicine
anti-diabetic medications for at least 90 days prior to visit 1, and are naïve to insulin therapy. Study participants had a HbA1c between ≥7.0% and ≤9.5% and a BMI of ≥23 kg/m2. All participants in the orforglipron treatment arms started the study at a dose of orforglipron 1 mg once-daily and then increased
More news about: Eli Lilly and Company
Jun 20, 2025, 19:30 ET Water Instead of Diet Drinks Associated with Two-Fold Rate of Diabetes Remission in Women
participants in the water group achieved diabetes remission, compared to 45% in the diet beverage group (P<0.0001). Additional health markers include BMI, fasting glucose, insulin levels, insulin resistance, postprandial glucose, and triglycerides also improved significantly in those who drank water.
More news about: American Diabetes Association
Jun 20, 2025, 19:30 ET Studies show promising results for individuals with type 2 diabetes and young children with type 1 diabetes on MiniMed™ 780G system
0.006 BMI, kg/m2 34.0 ± 7.3g
More news about: Medtronic plc
Jun 20, 2025, 11:37 ET Medical Imaging Equipment Market Size to Hit USD 62.51 Billion by 2031 with 4.5% CAGR | Business Market Insights
https://www.businessmarketinsights.com/ Logo - https://mma.prnewswire.com/media/2715706/BMI_Logo.jpg
More news about: Business Market Insights
Jun 18, 2025, 12:40 ET Polydeoxyribonudeotide (PDRN) Market to Surge with Anti-Aging & Regenerative Therapies Demand: Valuates Reports
BiologicalHENGYU BIOPHReaLi Tide BiologicalHTL BiotechnologyPharmaResearch Co., Ltd.HumedixDongkookBMI KOREAPurchase Regional Data:
More news about: Valuates Reports
Jun 18, 2025, 08:58 ET FDA Expands Indication for Levita Magnetics' Magnetic Surgical System with MARS® for Minimally Invasive Bariatric and Hiatal Hernia Repair
clearance also marks the release of Levita's new 12.5mm magnetic grasper, specifically engineered to improve visualization and control in patients with high BMI and large or difficult-to-retract livers. The device allows surgeons to grasp the liver more centrally, rather than from the edge, improving surgical
More news about: Levita Magnetics
Jun 18, 2025, 08:00 ET Mend Expands Upgraid™ to Address Obesity-Related Surgical Barriers and Drive Long-Term Wellness
and comorbidities have significant impacts on surgical delays and cancellations, particularly in orthopedic procedures. Many patients with elevated BMI are told they must lose weight before they can proceed with surgery, but few are given the tools to succeed. The enhanced Upgraid program now bridges
More news about: Mend Labs
Jun 17, 2025, 09:30 ET About Fresh and Neighborhood Healthcare Partner to Launch Innovative Fresh Connect Produce Prescription Pilot to Improve Health Outcomes for Diabetic Patients
improve overall health, and increase access to healthy foods. The program's main objectives include reducing A1c levels, decreasing body mass index (BMI), lowering blood pressure, and improving overall nutrition. The program also aims to increase patient satisfaction with their care. "Proper nutrition
More news about: About Fresh
Jun 15, 2025, 22:56 ET Innovent Announces Completion of First Participant Dosed in the Seventh Phase 3 Clinical Trial (GLORY-OSA) of Mazdutide in China
glucagon-like peptide-1 (GLP-1) receptor agonist, in Chinese participants with moderate-to-severe obstructive sleep apnea (OSA) and obesity (BMI ≥ 28 kg/m2). This is the seventh Phase 3 clinical study of mazdutide in China, continuing to explore its
More news about: Innovent Biologics
Jun 12, 2025, 09:00 ET Standard Industries Announces Molecule.one as Winner of $1 Million AI Challenge
Standard Building Solutions includes GAF, the largest roofing and waterproofing manufacturer in North America, and BMI, the largest manufacturer of both flat and pitched roofing in Europe, as well as Schiedel, SGI, and Standard Logistics.
More news about: Standard Industries